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Abstract
Objectives: Cryptococcal meningitis (CM)-related mortality may be prevented by screening patients for sub-clinical
cryptococcal antigenaemia (CRAG) at antiretroviral-therapy (ART) initiation and pre-emptively treating those testing
positive. Prior to programmatic implementation in South Africa we performed a cost-effectiveness analysis of alternative
preventive strategies for CM.
Design: Cost-effectiveness analysis.
Methods: Using South African data we modelled the cost-effectiveness of four strategies for patients with CD4 cell-counts
,100 cells/ml starting ART 1) no screening or prophylaxis (standard of care), 2) universal primary fluconazole prophylaxis, 3)
CRAG screening with fluconazole treatment if antigen-positive, 4) CRAG screening with lumbar puncture if antigen-positive
and either amphotericin-B for those with CNS disease or fluconazole for those without. Analysis was limited to the first year
of ART.
Results: The least costly strategy was CRAG screening followed by high-dose fluconazole treatment of all CRAG-positive
individuals. This strategy dominated the standard of care at CRAG prevalence$0.6%. Although CRAG screening followed by
lumbar puncture in all antigen-positive individuals was the most effective strategy clinically, the incremental benefit of LPs
and amphotericin therapy for those with CNS disease was small and additional costs were large (US$158 versus US$51per
person year; incremental cost effectiveness ratio(ICER) US$889,267 per life year gained). Both CRAG screening strategies are
less costly and more clinically effective than current practice. Primary prophylaxis is more effective than current practice, but
relatively cost-ineffective (ICER US$20,495).
Conclusions: CRAG screening would be a cost-effective strategy to prevent CM-related mortality among patients initiating
ART in South Africa. These findings provide further justification for programmatic implementation of CRAG screening.
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Introduction
Cryptococcal meningitis (CM) is one of the leading causes of
death in HIV-infected patients in Africa. CM accounts for
between 33% and 63% of all adult meningitis in southern Africa
[1–3], and acute mortality ranges from 24% to 50% [4–9]. As a
result CM is estimated to cause in excess of 500,000 deaths
annually in sub-Saharan Africa [10]. Prevention strategies are
therefore of great public health importance. Recent data from
South Africa suggest that the vast majority of patients who develop
CM are already in care with an established HIV diagnosis [11]
and that a sizeable proportion present following initiation of
antiretroviral therapy (ART) [4,6]. Thus, opportunities exist for
preventive interventions.
Timely initiation of (ART) resulting in immune reconstitution is
clearly the most effective strategy for preventing all HIV-related
opportunistic infections [12], and a marked decline in the
incidence of cryptococcal disease was seen in the developed world
following the introduction of effective ART [13–15]. Unfortu-
nately, despite recent progress in expanding access to ART in
South Africa, a substantial proportion of patients still present late
with advanced immunodeficiency and high risk of new AIDS
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events and mortality [16]. Thus, preventive interventions imple-
mented immediately before or concomitantly with ART, could be
an effective initial strategy in the treatment of patients with
advanced HIV, allowing patients the best chance at long-term
disease free survival.
Universal fluconazole primary prophylaxis in areas of high
incidence of cryptococcal disease has been shown to be highly
effective at reducing the incidence of CM [17–23]. However, no
study has yet shown a significant reduction in mortality [23]. The
inefficiency of this strategy with regard to the large numbers of
patients requiring treatment [17,24], high cost [25–29], and
concerns regarding drug resistance [29–32], has meant that such a
strategy has never been widely implemented.
More recently it has been shown that the vast majority of
patients at risk of developing CM during ART can be identified at
the time of entry into ART services by screening for sub-clinical
infection using simple and low-cost cryptococcal antigen (CRAG)
immunoassays on blood samples [33]. Current CRAG immuno-
assays are highly sensitive and specific, and CRAG screening at
ART initiation has been shown to be 100% sensitive and 96%
specific for predicting development of CM during the first year of
ART [33]. Patients identified during CRAG screening pre-ART
could be targeted with ‘‘pre-emptive’’ therapy to prevent the
development of severe disease. This strategy enables identification
of a limited number of patients at risk who can then receive
intensive investigation and treatment, avoiding the costs of
widespread and unnecessary drug exposure and the associated
risk of development of drug resistance [32].
To inform policy makers considering programmatic implemen-
tation of CM prevention strategies we performed a cost-
effectiveness analysis of four different strategies to prevent
cryptococcal meningitis in individuals initiating ART in South
Africa with CD4 cell-counts ,100 cells/ml: ART alone, with no
screening or prophylaxis (the current standard of care); universal
primary fluconazole prophylaxis; CRAG screening with targeted
high-dose fluconazole treatment for all patients testing positive; or
CRAG screening with subsequent lumbar puncture (LP) for those
testing positive and treatment either using amphotericin B for
those with infection of the central nervous system (CNS) or high-
dose fluconazole for those without.
Methods
Study Design
Using primarily South African data on CRAG prevalence, CM
incidence in ART programmes, CM-related mortality and health
service costs we modeled the cost-effectiveness of four strategies in
patients with CD4 cell-counts ,100 cells/ml: 1) no screening or
prophylaxis (standard of care), 2) universal primary prophylaxis
with fluconazole 200 mg daily, 3) CRAG screening with high-dose
fluconazole treatment for all patients testing positive (800 mg
fluconazole daily for two weeks, followed by 400 mg daily for eight
weeks, then 200 mg daily maintenance) and 4) CRAG screening
with lumbar puncture for all patients testing positive, amphoter-
icin-B 1 mg/kg/day for two weeks for those with CNS disease and
fluconazole 800 mg daily for two weeks for those without, in both
cases followed by fluconazole 400 mg daily for eight weeks, then
200 mg daily maintenance as above. A CD4 count cut-off of 100
cells/ml was used as nearly all cases of CM developing following
ART initiation occur in this patient group [33], and prevention
strategies will be targeted at this population. Incremental costs
were assessed from the provider’s perspective. We only included
the health care costs associated with the treatment and prevention
of CM. Outcomes were defined as life-years gained. Given our
restricted scope of provider costs, we also only considered deaths
from CM within our estimates of life-years gained. The main
summary measures used for presenting results were annual costs,
annual life years and incremental cost effectiveness ratios (ICER).
The latter is a ratio that summarizes the difference in costs to the
difference in life years. However, when a more effective
intervention is less costly than a comparator, it is said to dominate
the comparator, and no ICER is calculated.
Model
We modeled the costs and outcomes of our alternative strategies
within a Markov model using a monthly cycle length, and ran the
model for 12 cycles in order to calculate annual costs and annual
life years. While we have not used our model to extrapolate data
beyond the period of observed follow-up, a Markov modeling
framework has been chosen as it allows for the synthesis of data
from secondary sources and for sophisticated sensitivity analyses to
be performed [34–35]. A simplified version of the structure of the
Markov model is presented in Figure 1. (The full model is
presented in figure S1).
Transition Probabilities (see Table 1)
The CD4 cell count distribution of patients entering ART
programmes (split into #50 cells/mL and 51–100 cells/mL), was
from a cohort of patients entering the ART service based at a
public sector community clinic in Cape Town [33]. The
probability of a positive serum CRAG at baseline was determined
using data from seven African and two international cohort studies
[33,36–42] (and Govender unpublished), and the probability of
CRAG positive patients having evidence of CNS disease at LP
derived from the four published cohorts [36–37,41–42]. The
probability of developing CM was derived from two separate lines
of data. Initially data regarding the clinical course of untreated
cryptococcal antigenaemia in patients initiating ART was used to
ascertain the proportion of CRAG positive patients, stratified by
CD4 cell count, who subsequently develop CM [33,39]. These
probabilites were applied to the CRAG prevalence figures
described above and were then verified using reported cryptococ-
cal incidence data from sub-Saharan Africa [33,43–45]. In
addition to stratification into two categories of CD4 cell count to
enable sensitivity analysis (#50 cells/mL and 51–100 cells/mL),
transition probabilities relating to the development of CM were
varied according to time on ART to account for CD4 cell count
increases, and the acompanying reduction in risk of developing
CM. This time stratification was into 3 month blocks according to
time from ART initiation, and the data used was from a large
South African cohort [45]. The probability of death in patients
developing CM was derived from six South African studies [4–
6,8–9,46] and data from the South African Mycology Reference
Unit, National Institute for Communicable Diseases (Govender,
unpublished), with a slight weighting towards those reflecting
programmatic outcomes rather than research conditions.
Data from a Cochrane meta-analysis were used to determine
the relative risk of developing CM with primary fluconazole
prophylaxis. CRAG screening immediately prior to ART initia-
tion was found to be 100% sensitive at identifying patients at risk
of developing CM in our previously reported study [33].
Combining the data from all available published global literature
we assumed a relative risk of 0.1 for the development of CM in
CRAG-positive patients receiving high dose fluconazole pre-
emptive treatment [24,39,41–42,47]. The most comprehensive
management approach was assumed to be 100% effective at
preventing subsequent symptomatic CM. This entailed doing LPs
on all patients testing CRAG-positiveand treatment either with
Cost Effectiveness of CRAG Screening
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Figure 1. Simplified markov model structure. Transition probabilities are listed as C1, C2, S1 etc. Variable names, descriptions and values are
derived from table 1, as follows: S1 - Proportion with subclinical CM at baseline, CD4,50 cells/mL = 0.13, CD4 50–100 cells/mL = 0.03. S2 - Of those with
subclinical CM, Proportion with CSF infection= 0.5. P1 - Proportion starting ART with CD4,50 cells/ml = 0.5. C1 - Probability of developing CM, by
baseline CD4 category and time on ART: CD4,50 cells/ml = 252 per 1000 patient years (pyo) up to 3 months on ART, 72 per 1000 pyo 4–6 months on
ART, 36 per 1000 pyo 7–9 months on ART, 0 per 1000 pyo 10–12 months. CD4 50–100 cells/ml= 56 per 1000 pyo up to 3 months on ART, 16 per 1000
pyo 4–6 months on ART, 8 per 1000 pyo 7–9 months on ART, 0 per 1000 pyo 10–12 months. R1 - Relative risk of CM with low dose fluconazole
prophylaxis = 0.21. R2 - Relative risk of CM for CRAG positive taking high dose fluconazole prophylaxis = 0.1. R3 - Relative risk of CM for CRAG positive
with amphotericin for CSF positive patients, fluconazole for CSF negative patients = 0. D1 - Probability of dying of acute CM=45% dead at 1 month
with CM. D2 - Probability of dying of CM within 1 year = 55% dead at 12 months on ART.
doi:10.1371/journal.pone.0069288.g001
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amphotericin for those with evidence of CNS disease or high-dose
fluconazole for those without.
Costs (see Table 2)
A micro costing approach was used: the ingredients of each
intervention (e.g. number of lab tests, dosages of medication etc)
were combined with the unit cost of each ingredient to calculate a
monthly cost per Markov state, and ultimately a cost per patient-
year within each intervention arm. Costs included prophylactic
medication (fluconazole, at varying doses), screening costs (CRAG
screening test plus titre, lumbar punctures), and treatment costs for
those developing CM (including inpatient care, outpatient
department visits, inpatient medication and tests). Medication
costs were from government tender prices, test costs were from the
National Health Laboratory Services, and lumbar puncture costs
were based on the Uniform Patient Fee Schedule. The overhead
and staff cost per inpatient day at the secondary level and the
overhead and staff cost per outpatient department visit was taken
from Cleary et al [48]. The overhead components of these costs
were inflated using the Consumer Price Index, while clinical staff
costs were recalculated using 2010 government salary scales. Costs
were expressed in 2010 prices, and were converted to United
States Dollars (US$) based on the average exchange rate between
1 January and 31 December 2010 (US$1=ZAR7.34; www.oanda.
com).
Uncertainty and Sensitivity Analysis
The literature identifies two sources of uncertainty that are
relevant to this study: the dataset, and the generalizability of results
[49]. Uncertainty relating to the data has been assessed using
probabilistic sensitivity analysis (PSA). Where possible, distribu-
tions (uncertainty intervals) were specified on utilisation, and
transition probability variables, and uncertainty was captured by
running 100,000 second-order Monte Carlo simulations. We have
not assessed uncertainty associated with discounting as the time
horizon of this study precluded any need for discounting. Finally,
we have sought to strengthen the generalizability of our results
through additional one- and multi-way simple sensitivity analyses.
All analyses were run in TreeAge Pro 2006.
Results
Outcomes
Outcomes at the end of the twelve month cycle were
determined using the transition probabilities listed in table 1. Risk
of developing CM varied by baseline CD4 category and time on
ART, with an overall probability of developing CM of 0.09 in
Table 1. Baseline input assumptions and transition probabilities.
Input Value Reference
Mean CD4 count 50 cells/ml Jarvis et al. CID 2009 48:856-62; Longley 2011 unpublished
Prevalence of cryptococcal antigenaemia 8% Desmet et al. AIDS 1988 3:77-8; Tassie et al. JAIDS 2003 33:411-2; Liechty et al.
TMIH 2007 12:929-35; Micol et al. JAIDS 2007 45:555-9; Jarvis et al. CID 2009
48:856-62; Pongsai et al. J Infect 2010 60:474-7; Meya et al. CID 2010 51:448-55;
Govender 2011 unpublished
Incidence of CM* 55/1000 pyo French et al. AIDS 2002 16:1031-8; Holmes et al. JAIDS 2006 42:464-9; Jarvis et al.
CID 2009 48:856-62; Jarvis et al. CID 2010 51:1463-5
CD4,50 cells/ml
0–3 months on ART 252/1000 pyo Jarvis et al. CID 2009 48:856-62; Jarvis et al. CID 2010 51:1463-5
4–6 months on ART 72/1000 pyo
7–9 months on ART 36/1000 pyo
.10 months on ART 0/1000 pyo
CD4 50–100 cells/ml
0–3 months on ART 56/1000 pyo Jarvis et al. CID 2009 48:856-62; Jarvis et al. CID 2010 51:1463-5
4–6 months on ART 16/1000 pyo
7–9 months on ART 8/1000 pyo
.10 months on ART 0/1000 pyo
Duration of hospitalization with CM 15 days (13–20) Jarvis et al. J Infect 2010 60:496-498
Mortality of CM 45% acute; 55% at
1 year
Jarvis et al. J Infect 2010 60:496-498; Bicanic et al. CID 2007 45:76-80; Bicanic et al.
CID 2008 47:123-30; Jarvis et al. CROI 2011 P-123; Lightowler et al. PLoS ONE 2010
5:e8630; Lessells et al. SAMJ 2011 101:251-252; Govender 2011 unpublished
Proportion CRAG +ve with CNS disease 50% Desmet et al. AIDS 1988 3:77-8; Tassie et al. JAIDS 2003 33:411-2; Pongsai et al. J
Infect 2010 60:474-7; Micol et al. JAIDS 2007 45:555-9
Relative risk of CM with primary fluconazole
prophylaxis
0.21 Chang et al. Cochrane Database Syst Rev 2005 CD004773.
Relative risk of CM with CRAG screening and high
dose fluconazole
0.1 Meya et al. CID 2010 51:448-55; Pongsai et al. J Infect 2010 60:474-7; Micol et al.
JAIDS 2007 45:555-9; Feldmesser et al. CID 1996 23:827-30; Yuen et al. CID 1994
19:579; Longley et al CID 2008 47:1556-61
Relative risk of CM with CRAG screening plus LP 0.0
*The incidence of CM varied according to CD4 count strata, and time on ART to account for CD4 cell count increases and the acompanying reduction in risk of
developing CM. The time stratification was into 3 month blocks according to time from ART initiation, and the data used to derive these probabilities was from a large
South African cohort [45].
doi:10.1371/journal.pone.0069288.t001
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patients with CD4 counts ,50 cells/mL and 0.02 in those with
CD4 counts of 50–100 cells/mL. Using these input parameters, in
the standard of care strategy the probability of dying from CM
during the first year of ART was 1.87% (95% CI 1.0–2.8%). This
is in keeping with data suggesting that mortality during the first
year of ART is in the range of 8–26% in resource limited settings,
and that CM accounts for up to 20% of this mortality [16]. The
most effective strategy for preventing mortality due to CM in this
model was CRAG screening with lumbar puncture of all CRAG
positive patients, followed by CRAG screening with high dose
fluconazole, then primary prophylaxis (see table 3).
Costs
The costs associated with each Markov state are outlined in
Table 2. The table indicates the resources that are needed for each
of the screening, prophylactic and treatment options, as well as the
full cost for each. Overall costs for each strategy, expressed as
mean costs per patient/year in the ART programme, were
US$51.41 for CRAG screening with targeted treatment of CRAG
Table 2. Costs.
Markov state Description Resource usage Unit cost (US$)*
On ART General state for patients on ART None 0
Flucon Tunnel states to capture time-variant costs
of primary fluconazole prophylaxis
Fluconazole 200 mg per day for 12 months 497.50
CRAG screening Temporary (1 cycle) state to capture
costs of CRAG screening
1 cryptococcal antigen test plus titre 10.86
CRAG + Tunnel states to capture time-variant
costs of targeted fluconazole for CRAG
positive patients
Fluconazole 800–1200 mg per day for 14 days; Fluconazole
400 mg per day for
56 days; Fluconazole 200 mg per day for remaining period up to
12 months
631.07
CRAG 2 General state for CRAG negative
patients
None 0
CRAG and LP
screening
Temporary (1 cycle) state to capture costs
of CRAG and LP screening
1 cryptococcal antigen test plus titre 10.86
For those positive: 1 lumbar puncture 17.04
CRAG +
CSF +
Tunnel states to capture time-variant costs
of inpatient and fluconazole treatment for
CRAG and CSF positive patients
Hotel costs over 15 inpatient days 2,266.03
4 full blood counts 26.59
1 litre saline IV over 14 inpatient days 19.04
50 mg amphotericin B over 14 inpatient days 54.32
1 lumbar puncture 17.04
4 creatinine, electrolyte, urea tests 53.02
Fluconazole 400 mg per day for 56 days; Fluconazole 200 mg
per day
for remaining period up to 12 months
554.74
CRAG +
CSF 2
Tunnel states to capture time-variant costs
of targeted fluconazole for CRAG positive
and CSF negative patients
Fluconazole 800–1200 mg per day for 14 days; Fluconazole 400 mg
per day for
56 days; Fluconazole 200 mg per day for remaining period up
to 12 months
631.07
CRAG 2 As above
CM Temporary (1 cycle) state for patients
with CM
Hotel costs over 15 inpatient days 2,266.03
4 full blood counts 26.59
1 litre saline IV over 14 inpatient days 19.04
50 mg amphotericin B over 14 inpatient days 54.32
2 lumbar punctures 34.08
4 creatinine, electrolyte, urea tests 53.02
2 outpatient department visits 51.74
Post CM Tunnel state for patients receiving
secondary fluconazole prophylaxis after
inpatient care for CM
Fluconazole 400 mg per day for 56 days; Fluconazole 200 mg
per day
for remaining period up to 12 months
554.74
*Medication costs were from government tender prices, test costs were from the National Health Laboratory Services, and lumbar puncture costs were based on the
Uniform Patient Fee Schedule. The overhead and staff cost per inpatient day at the secondary level and the overhead and staff cost per outpatient department visit was
taken from Cleary et al [48]. The overhead components of these costs were inflated using the Consumer Price Index, while clinical staff costs were recalculated using
2010 government salary scales. Costs were expressed in 2010 prices, and were converted to United States Dollars (US$) based on the average exchange rate between 1
January and 31 December 2010 (US$1 =ZAR7.34; www.oanda.com).
doi:10.1371/journal.pone.0069288.t002
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positive individuals with high dose fluconazole; US$157.53 for
CRAG screening with lumbar puncture (LP) in all CRAG positive
individuals and amphotericin B for those with evidence of central
nervous system (CNS) infection, and high dose fluconazole for
those without; US$207.36 for standard of care (no prevention
intervention); and US$582.41 for universal primary prophylaxis
(table 3). The cost of the standard of care strategy was driven
almost entirely by inpatient treatment of patients developing CM,
while in both the CRAG screening with targeted treatment of
CRAG positive individuals with high dose fluconazole and
primary prophylaxis strategies costs were almost exclusively for
prevention in out-patient settings (figure 2).
Cost-effectiveness
Over the twelve month cycle modelled, both screen and treat
strategies were more effective and less expensive than the current
standard of care and universal primary prophylaxis (i.e ‘‘domi-
nated’’ – see table 3). CRAG screening with lumbar puncture in all
CRAG positive individuals was the most effective strategy, and less
costly than the current standard of care. However CRAG
screening with targeted treatment of CRAG positive individuals
with high dose fluconazole was only marginally less effective, while
being considerably less expensive (US$ 51.41 versus US$157.53),
leading to a high incremental cost-effectiveness ratio. Primary
prophylaxis was more expensive and more effective than the
current standard of care (US$582.41 per patient/year versus
US$207.36, with an ICER of US$20,494.54 per life year gained).
Sensitivity Analysis
One-way sensitivity analyses were conducted to determine how
sensitive the results were to changes in baseline CRAG prevalence
(table 3 and figure 3) and rates of loss to follow-up in the ART
programme. Increasing loss to follow-up rates to 50% increased
the cost of CRAG screening with targeted treatment of all CRAG
positive individuals with high dose fluconazole to US$135.07 and
increased the probability of death due to CM to 0.8%; however
the strategy still dominated the standard of care (the costs for
which would remain basically unchanged). Assuming the baseline
prevalence of cryptococcal antigenaemia was less than 1% had
limited effect on the overall results, with CRAG screening with
targeted treatment of all CRAG positive individuals with high dose
fluconazole dominating the standard of care to CRAG prevalence
of 0.6%, and CRAG screening with lumbar puncture dominating
standard of care to CRAG prevalence of 2.5% (figure 3).
Table 3. Cost-effectiveness.
Table 3 (A). Cost-effectiveness of strategies to prevent cryptococcal meningitis in South Africa
Mean cost (US$) 95% CI* Life years 95% CI*
Incremental cost-
effectiveness ratio (ICER)
CRAG screening with high dose fluconazole 51.41 39.14–64.46 0.9999 0.9992–1 ––
CRAG screening with lumbar puncture 157.53 111.92–207.94 1 889,266.69
Standard of care 207.36 158.38–261.36 0.9813 0.9718–0.99 (Dominated) {
Universal primary prophylaxis 582.41 578.49–590.39 0.9996 0.9983–1 (Dominated){
Table 3 (B). Sensitivity analysis: impact of varying the prevalence of cryptococcal antigenaemia in the population
Mean cost (US$) Life years ICER
Decreasing baseline antigen prevalence to 6%
CRAG screening with fluconazole 41.27 0.999
CRAG screening with lumbar puncture 120.86 1 889,185.26
Standard of care 157.07 0.9859 (Dominated)
Universal primary prophylaxis 581.43 0.9997 (Dominated)
Decreasing baseline antigen prevalence to 4%
CRAG screening with fluconazole 31.14 0.9999
CRAG screening with lumbar puncture 84.19 1 889,087.45
Standard of care 105.75 0.9905 (Dominated)
Universal primary prophylaxis 580.45 0.9998 (Dominated)
Decreasing baseline antigen prevalence to 2%
CRAG screening with fluconazole 21.00 1
CRAG screening with lumbar puncture 47.53 1 889,083.68
Standard of care 53.40 0.9952 (Dominated)
Universal primary prophylaxis 579.47 0.9999 (Dominated)
Mean cost =Mean per-patient cost for prevention and/or treatment of CM, US$, during first year of ART.
Life years =Mean life expectancy one year after ART programme entry.
ICER = ratio of difference in cost to difference in outcome.
*Uncertainty interval.
{Higher cost than more effective option(s).
doi:10.1371/journal.pone.0069288.t003
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Discussion
This study suggests that CRAG screening of blood from patients
entering ART programmes and targeted treatment of those testing
positive would be a cost-effective intervention in South Africa,
saving both money and lives when compared to the current
standard of care. Although the most effective strategy for
preventing CM is CRAG screening followed by LP for all patients
identified as having asymptomatic cryptococcal antigenaemia, the
incremental benefit of performing LPs and giving amphotericin
based therapy for those identified as having CNS disease is small,
while the additional costs are large. Both CRAG screening
strategies are more cost-effective than current standard of care.
However the most feasible and economically most favourable
strategy was to screen all patients entering ART programmes with
CD4 cell counts less than 100 cells/ml for CRAG, with targeted
treatment of all CRAG positive individuals with high dose
fluconazole. From a public health perspective this may be the
best and most feasible approach to implement, and sensitivity
analysis demonstrates such a screen and treat strategy is both less
costly and more effective than the current standard of care in
settings with antigen prevalences as low as 0.6% - well below the
lower reported antigen prevalence figures of 4% (figure 3). Given
the small but important benefit gained at the level of the individual
patient by performing LPs and offering more aggressive treatment,
in well resourced settings where this is possible, it may also be an
attractive strategy. Again this is less costly and more effective than
Figure 2. Cost Breakdown. The cost of each of the four strategies divided into screening costs, preventive treatment (or ‘‘prevention’’) costs and
treatment costs. Screening costs (black shading) include all costs associated with CRAG screening including the CRAG assay. Prevention costs (grey
shading) include all costs associated with prevention including universal fluconazole in the primary prophylaxis strategy; and fluconazole pre-emptive
treatment for CRAG positive patients, LPs, clinic visits and in-patient amphotericin for screened patients with CNS involvement in the screen and treat
strategies. Treatment costs (cross-hatched shading) include all costs associated with treatment of CM in patients who develop clinical CM. Costs are
as outlined in table 2, and expressed as mean cost per patient/year in the ART programme.
doi:10.1371/journal.pone.0069288.g002
Figure 3. Sensitivity analysis by background antigen prevalence. The results of one-way sensitivity analysis varying the background
cryptococcal antigen prevalence in patients entering ART programmes with CD4 cell counts ,100 cells/mL. The cost of current standard of care (no
prevention, or status quo) is shown by the dotted line, and the cost of the CRAG screening with targeted treatment of CRAG positive individuals with
high dose fluconazole (no LPs) is shown by the solid line. The screen and treat strategy dominated the standard of care at antigen prevalences of
0.6% and higher. The shaded area represents the range of baseline CRAG prevalence figures reported in patients with CD4 counts ,100 cell/mL at
ART programme entry. Costs are expressed as mean cost per patient/year in the ART programme.
doi:10.1371/journal.pone.0069288.g003
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the current standard of care with an antigen prevalence as low as
2.5%.
Universal primary fluconazole prophylaxis has previously been
clearly shown to reduce the incidence of CM [22–23]. However,
using South African costing and incidence data, this is the least
cost-effective cryptococcal prevention strategy, not only costing
considerably more than either CRAG screening approach, but
also was less effective at preventing CM. The high cost of universal
primary prophylaxis is primarily driven by the cost of preventive
fluconazole, even though the lowest available generic drug prices
are utilized in the analysis. This finding is in keeping with the
results from prior cost-effectiveness analyses of fluconazole
primary prophylaxis which have generally been unfavourable.
Estimates range from US$70,000 to US$240,000 per quality
adjusted life year (QALY) gained [25–28], even assuming high
incidence rates and high efficacy of prophylaxis.
Two other published analyses have examined the cost
effectiveness of CRAG screening and targeted preventive treat-
ment, and in keeping with this analysis both concluded that
antigen screening is a cost-effective strategy to prevent HIV-
associated CM in patients with CD4 cell counts below 100 cells/
mL [39,50]. Meya et al estimated that in Uganda the number of
patients who would need to be CRAG screened and fluconazole
treated to prevent one case of CM was 11.3 at a cost of US$190,
or, to save one life, 15.9 patients at a cost of US$266. This equated
to US$21 per disability adjusted life year (DALY) gained [39]. An
important caveat to these data is that no allowance was made for
the avoided costs of in-patient amphotericin B treatment inherent
in the screening strategy, hence the true cost-effectiveness of
CRAG screening may have been underestimated [45]. Micol et al,
in Cambodia, also found CRAG screening to be a cost-effective
intervention, costing US$180 per life year gained when compared
to no intervention. As in our South African analysis, primary
fluconazole prophylaxis was shown to be less cost-effective than
CRAG screening in Cambodia [50].
Our analysis differs from the two previous cost-effectiveness
analyses in several important respects. We have modelled the
impact of high dose fluconazole pre-emptive therapy in the CRAG
screening arm, which is an approach based on the best evidence
available and the strategy being proposed for implementation at a
national level in South Africa (Southern African HIV Clinicians
Society Guidelines, in preparation). We have also examined the
impact on costs and outcomes of performing LPs as part of the
CRAG screening intervention. These are strengths of the analysis
as they address the practically relevant clinical and programmatic
questions facing clinicians and policy makers. Further strengths of
this analysis are the robustness of the underlying clinical and
costing assumptions. Data on CRAG prevalence and outcomes are
derived from the largest reported prospective cohort [33] and
extensive southern African data on incidence, natural history and
outcomes of cryprococcal infections. This has been combined with
accurate costing data from the South African public health care
sector [48], which while potentially limiting the generalizability of
these data to settings outside southern Africa, provides the first
detailed information for policy makers in the area of the world
with the highest burden of cryptococcal disease.
As with all analyses of this type, the primary limitations relate to
the necessity to make underlying assumptions based on data from
a variety of sources. However the data from which the transition
probabilities were generated is, wherever possible, from large and
well-conducted clinical trials and cohort studies. Estimates of
CRAG prevalence, cryptococcal incidence and cryptococcal
disease outcomes were derived from a large body of published
work. Outcomes without preventive measures in place reflect data
reported from South Africa and the impact of primary prophylaxis
was derived from a meta-analysis. Fewer data regarding the
efficacy of CRAG screening were available; hence the estimates
used are subject to greater uncertainty. However, the estimates
used take into account all currently available evidence. The
sensitivity analyses performed demonstrate that even with wide
variations in CRAG prevalence, access to effective treatments and
rates of follow-up, the key findings about relative costs and
effectiveness remain unchanged.
A growing body of evidence is emerging to support the use of
CRAG screening as a tool to prevent CM. This study adds further
weight to this evidence, showing that CRAG screening would be a
highly cost-effective intervention in South Africa, the country with
the highest burden of HIV in the world. These findings, along with
other reported studies [33,45] strongly support the implementa-
tion of CRAG screening within the South African ART
programme. The most cost-effective strategy of CRAG screening
with targeted high dose fluconazole for those testing positive would
be cost saving compared to the current standard of care, is
practical, and easily implementable. Recently developed low-cost
and simple point-of-care CRAG tests [51] have not been
considered in this analysis as they were not available during the
study period, but cost approximately two-fold less than the CRAG
pricing used in this study. This promises to make CRAG screening
feasible in an even wider range of settings and at lower cost. A
further impact of implementing CRAG screening is that pre-
emptive treatment in primary care would reduce the burden and
major costs associated with treatment of overt cryptococcal disease
in secondary level care [52,53]. This would not only reduce overall
costs, but would also shift costs to the preventive primary care
level.
In conclusion this analysis has shown that CRAG screening
would be a highly cost-effective strategy to prevent CM-related
mortality among patients initiating ART in South Africa. The
most cost-effective, as well as the most practical, approach is
provision of high dose fluconazole for all CRAG-positive patients.
These findings provide strong justification for the programmatic
implementation of CRAG screening in South Africa and are likely
to be applicable in other settings of high HIV and CM incidence.
Supporting Information
Figure S1 Full Markov Model. Full Markov model showing
the four cryptococcal prevention strategies - 1) no screening or
prophylaxis (standard of care or status quo), 2) universal primary
prophylaxis with fluconazole 200mg daily, 3) CRAG screening
with high-dose fluconazole treatment for all patients testing
positive (800mg fluconazole daily for two weeks, followed by
400mg daily for eight weeks, then 200mg daily maintenance) and
4) CRAG screening with lumbar puncture for all patients testing
positive, amphotericin-B 1mg/kg/day for two weeks for those with
CNS disease and fluconazole 800mg daily for two weeks for those
without, in both cases followed by fluconazole 400mg daily for
eight weeks, then 200mg daily maintenance as above.
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